Disease · MONDO_0001660

proliferative diabetic retinopathy

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. proliferative diabetic retinopathy. Diseases, record MONDO_0001660. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001660

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: proliferative diabetic retinopathy; Open Targets
Open Targets ID: MONDO_0001660; Open Targets
Other names: PDR; Open Targets
Disease Ontology: DOID:13207; Disease Ontology
NCI Thesaurus: C84457; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 9 of its 24 drugs, from ClinicalTrials.gov; Open Targets

Drugs24

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
RANIBIZUMAB	CHEMBL1201825	Antibody	Phase 3	ClinicalTrials.gov	21	21	20	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 3	ClinicalTrials.gov	18	18	17	Drugs and targets
AFLIBERCEPT	CHEMBL1742982	Protein	Phase 3	ClinicalTrials.gov	12	12	12	Drugs and targets
TRIAMCINOLONE ACETONIDE	CHEMBL1504	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
PEGAPTANIB SODIUM	CHEMBL1201421	Small molecule	Phase 3	ClinicalTrials.gov	3	3	1	Drugs and targets
FARICIMAB	CHEMBL4297750	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
OCTREOTIDE ACETATE	CHEMBL1200480	Protein	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
BROLUCIZUMAB	CHEMBL3707357	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CANDESARTAN	CHEMBL1016	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SODIUM CHLORIDE	CHEMBL1200574	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 24

See all 24 drugs

Targets19

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
VEGFA	Vascular endothelial growth factor A, long form	7	Vascular endothelial growth factor A antagonist; Vascular endothelial growth factor A inhibitor	Phase 3	https://conductscience.org/library/genes/7422	Drugs and targets
NR3C1	Glucocorticoid receptor	2	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908	Drugs and targets
PGF	Placenta growth factor	2	Placenta growth factor inhibitor	Phase 3	https://conductscience.org/library/genes/5228	Drugs and targets
RPE65	Retinoid isomerohydrolase	2	Retinoid isomerohydrolase inhibitor	Phase 2	https://conductscience.org/library/genes/6121	Drugs and targets
SSTR1	Somatostatin receptor	2	Somatostatin receptor agonist	Phase 3	https://conductscience.org/library/genes/6751	Drugs and targets
SSTR2	Somatostatin receptor	2	Somatostatin receptor agonist	Phase 3	https://conductscience.org/library/genes/6752	Drugs and targets
SSTR3	Somatostatin receptor	2	Somatostatin receptor agonist	Phase 3	https://conductscience.org/library/genes/6753	Drugs and targets
SSTR4	Somatostatin receptor	2	Somatostatin receptor agonist	Phase 3	https://conductscience.org/library/genes/6754	Drugs and targets
SSTR5	Somatostatin receptor	2	Somatostatin receptor agonist	Phase 3	https://conductscience.org/library/genes/6755	Drugs and targets
ADRB1	Beta-1 adrenergic receptor	1	Beta-1 adrenergic receptor antagonist	Phase 1	https://conductscience.org/library/genes/153	Drugs and targets

1 to 10 of 19

See all 19 targets

Trials65

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00252720	DIabetic Retinopathy Candesartan Trials.	Phase 3	1,850	2014-06-03	Type 1 Diabetes	CANDESARTAN	Its record names the disease	ClinicalTrials.gov
NCT04278417	Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy	Phase 3	689	2024-08-20	Proliferative Diabetic Retinopathy	BROLUCIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01331681	Intravitreal Aflibercept Injection in Vision Impairment Due to DME	Phase 3	406	2014-09-09	Diabetes Mellitus, Macular Edema	AFLIBERCEPT	Its record names the disease	ClinicalTrials.gov
NCT00445003	Laser-Ranibizumab-Triamcinolone for Proliferative Diabetic Retinopathy	Phase 3	333	2011-07-13	Proliferative Diabetic Retinopathy, Diabetic Macular Edema	RANIBIZUMAB, TRIAMCINOLONE ACETONIDE	Its record names the disease	ClinicalTrials.gov
NCT01489189	Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy	Phase 3	305	2016-06-01	Proliferative Diabetic Retinopathy	RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00996437	Intravitreal Ranibizumab for Vitreous Hemorrhage Due to Proliferative Diabetic Retinopathy (N)	Phase 2/3	261	2013-05-16	Vitreous Hemorrhage, Proliferative Diabetic Retinopathy	RANIBIZUMAB, SODIUM CHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT02858076	Anti-VEGF vs. Prompt Vitrectomy for VH From PDR	Phase 2/3	205	2021-01-19	Proliferative Diabetic Retinopathy, Vitreous Hemorrhage	AFLIBERCEPT	Its record names the disease	ClinicalTrials.gov
NCT01131585	Safety and Efficacy of Ranibizumab in Diabetic Macular Edema	Phase 3	128	2012-08-17	Visual Impairment Due to Diabetic Macular Edema	RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00745498	Pre- and Intra-operative Intravitreal Bevacizumab Injection in Diabetic Vitrectomy	Not applicable	126	2015-12-21	Proliferative Diabetic Retinopathy, Vitreous Hemorrhage	BEVACIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT01594281	Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE)	Phase 2	107	2019-03-15	Proliferative Diabetic Retinopathy (PDR)	RANIBIZUMAB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 65

See all 65 trials

Comparisons in its trials28

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Candesartan vs Placebo: Number of Participants With a 3-step or Greater Increase in Early Treatment of Diabetic Retinopathy Study (EDTRS) Severity Scale	127 of 951	124 of 954	1,905	NCT00252720	Trial comparisons
Candesartan vs Placebo: Number of Participants With Incident Clinically Significant Macular Edema (CSME) and/or Proliferative Diabetic Retinopathy (PDR).	110 of 951	107 of 954	1,905	NCT00252720	Trial comparisons
Candesartan vs Placebo: Number of Participants With a Regression of Diabetic Retinopathy.	140 of 951	139 of 954	1,905	NCT00252720	Trial comparisons
Candesartan vs Placebo: serious adverse events	173 of 951	161 of 951	1,902	NCT00252720	Trial comparisons
Brolucizumab 6 mg vs Panretinal Photocoagulation Laser Arm: Number and Percentage of Subjects With Center-involved Diabetic Macular Edema (CI- DME) up to Week 54 for the Study Eye	108 of 347	248 of 341	688	NCT04278417	Trial comparisons
Brolucizumab 6 mg vs Panretinal Photocoagulation Laser Arm: Number and Percentage of Subjects With Center-involved Diabetic Macular Edema (CI- DME) up to Week 96 for the Study Eye	126 of 347	262 of 341	688	NCT04278417	Trial comparisons
Brolucizumab 6 mg vs Panretinal Photocoagulation Laser Arm: Number and Percentage of Subjects With no Proliferative Diabetic Retinopathy (PDR) at Week 96 for the Study Eye	188 of 310	86 of 303	613	NCT04278417	Trial comparisons
Brolucizumab 6 mg vs Panretinal Photocoagulation Laser Arm: Number and Percentage of Subjects With no Proliferative Diabetic Retinopathy (PDR) at Week 54 for the Study Eye	187 of 294	65 of 290	584	NCT04278417	Trial comparisons
Ranibizumab vs Saline Injection: serious adverse events	13 of 125	23 of 136	261	NCT00996437	Trial comparisons
Intravitreous 2 mg Aflibercept Injections vs Prompt Vitrectomy Plus Panretinal Photocoagulation: deaths from any cause	6 of 100	3 of 105	205	NCT02858076	Trial comparisons

1 to 10 of 28

See all 28 comparisons in its trials

Papers from its trials54

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37021018	RESULT	1	PubMed
37007930	RESULT	1	PubMed
26802783	RESULT	1	PubMed
26565927	RESULT	1	PubMed
26198808	RESULT	1	PubMed
26056030	RESULT	1	PubMed
25439614	RESULT	1	PubMed
25012934	RESULT	1	PubMed
24379924	RESULT	1	PubMed
24339677	RESULT	1	PubMed

1 to 10 of 54

See all 54 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001660

GET https://conductscience.org/api/diseases/v1/MONDO_0001660/drugs?page=2

API reference For AI assistants